Abstract
This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal
-
Antibodies, Viral
-
COVID-19*
-
Humans
-
Spike Glycoprotein, Coronavirus
-
United States
-
United States Food and Drug Administration
Substances
-
Antibodies, Monoclonal
-
Antibodies, Viral
-
Spike Glycoprotein, Coronavirus
-
spike protein, SARS-CoV-2